Subscribe free

Upper Gastrointestinal Tract ·

Survival Advantage in Esophageal Cancer: FLOT vs CROSS

Patients with esophageal adenocarcinoma achieving pathological complete response show better outcomes with FLOT chemotherapy compared to CROSS chemoradiotherapy.

  • FLOT patients had a significantly lower recurrence rate (8.8%) vs. CROSS (24.7%).
  • Overall survival was much better in the FLOT group, with a hazard ratio of 0.34 after adjustment.

Surgeons should consider FLOT for better long-term survival and lower recurrence likelihood in eligible patients.

  • Distant metastases were more common in the CROSS group, highlighting differing recurrence patterns.

Journal Article by Alhayo S, Chou WK (…) van Berge Henegouwen MI et 53 al. in JAMA Surg

read the whole article in JAMA Surg

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Upper Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Upper Gastrointestinal Tract

The latest stitches

Ann Surg Oncol2 Nov 2026

High symptom burden after oesophagectomy

On postoperative day 3, about one in five patients had high symptom burden, and the symptoms most linked to others differed between patient groups.

J Gastrointest Cancer23 Oct 2026

Uniportal esophagectomy linked to fewer pneumonias

In nine comparative studies of minimally invasive esophagectomy for esophageal cancer, uniportal VATS was associated with less pneumonia and a shorter stay than multiportal VATS—but the evidence is not strong enough to establish a preferred approach.

All papers in Upper Gastrointestinal Tract →